HIGHLIGHTS
- who: Stefan D. Anker from the (UNIVERSITY) have published the paper: Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved, in the Journal: (JOURNAL)
- what: The authors report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (u2265 50%) (n=4,005; 66.9%) or mid-range (41-49%). Given the effect modification by baseline LVEF seen in previous trials, the aim of this pre-specified analysis of the EMPEROR-Preserved trial was to document the effect . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.